论文部分内容阅读
急性冠状动脉综合征(ACS)为临床常见危重症,对患者的生命安全构成严重威胁。近年来,随着医学发展进步,使得ACS的生理病例开始不断被人们熟知,其普遍认为易损斑块破裂和继发性血栓是导致ACS发病的主要机制,临床治疗中,大多会采取抗凝治疗与再灌注两个策略,抗凝治疗,也是急性冠脉综合征的预防手段,ACS患者在出院后,都会接受抗凝治疗。在行抗凝治疗后,急性冠脉综合征的急性期、围手术期等时间都会减少风险。但是目前,在ACS患者中使用抗凝治疗的相关资料较少,其使用后是否能够对患者预后进行改善,尚未出现明确定论。本文主要以急性冠脉综合征病理生理开始,对抗凝药物对ACS治疗效果进行对比分析。
Acute coronary syndrome (ACS) is a common clinical critically ill, posing a serious threat to the patient’s life safety. In recent years, with the development of medicine, making the physiological cases of ACS continue to be well known, it is generally believed that vulnerable plaque rupture and secondary thrombosis is the main mechanism leading to the pathogenesis of ACS, most of the clinical treatment will take anticoagulation Treatment and reperfusion two strategies anticoagulant therapy, but also the prevention of acute coronary syndromes, ACS patients will be discharged after the discharge of anticoagulant therapy. In the line of anticoagulant therapy, acute coronary syndrome, acute, perioperative period will reduce the risk. However, at present, there is less data on the use of anticoagulant therapy in patients with ACS, and whether there is any improvement in the prognosis of patients after the use of it has not yet been conclusive. This article mainly in the pathophysiology of acute coronary syndrome began anticoagulant drugs for ACS treatment effect were compared.